High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.

Juan José Castón, Francisco González-Gasca, Lourdes Porras, Soledad Illescas, Maria Dolores Romero, Julio Gijón
{"title":"High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.","authors":"Juan José Castón,&nbsp;Francisco González-Gasca,&nbsp;Lourdes Porras,&nbsp;Soledad Illescas,&nbsp;Maria Dolores Romero,&nbsp;Julio Gijón","doi":"10.3109/00365548.2014.931596","DOIUrl":null,"url":null,"abstract":"<p><p>We retrospectively investigated the impact of high vancomycin minimum inhibitory concentration (MIC > 2 μg/ml) on the outcome of 53 patients with bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA). Vancomycin MIC was determined by broth microdilution according to CLSI methods. The primary outcome was 30-day all-cause mortality from the date of the first positive blood culture. The mortality rate was 22.6% (12 of 53 patients). High vancomycin MIC (odds ratio (OR) = 9.3; 95% confidence interval (95% CI) = 1.31-63.20; p = 0.027), Charlson comorbidity index ≥ 3 (OR = 10.3; 95% CI = 1.3-102.04; p = 0.03), advanced age (OR = 35.8; 95% CI = 2.3-659.2; p = 0.01), and severe sepsis (OR = 8.5; 95% CI = 1.2-61.4; p = 0.03) were associated with mortality.</p>","PeriodicalId":21541,"journal":{"name":"Scandinavian Journal of Infectious Diseases","volume":"46 11","pages":"783-6"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365548.2014.931596","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00365548.2014.931596","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/8/19 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

We retrospectively investigated the impact of high vancomycin minimum inhibitory concentration (MIC > 2 μg/ml) on the outcome of 53 patients with bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA). Vancomycin MIC was determined by broth microdilution according to CLSI methods. The primary outcome was 30-day all-cause mortality from the date of the first positive blood culture. The mortality rate was 22.6% (12 of 53 patients). High vancomycin MIC (odds ratio (OR) = 9.3; 95% confidence interval (95% CI) = 1.31-63.20; p = 0.027), Charlson comorbidity index ≥ 3 (OR = 10.3; 95% CI = 1.3-102.04; p = 0.03), advanced age (OR = 35.8; 95% CI = 2.3-659.2; p = 0.01), and severe sepsis (OR = 8.5; 95% CI = 1.2-61.4; p = 0.03) were associated with mortality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
万古霉素最低抑制浓度高与甲氧西林敏感金黄色葡萄球菌菌血症患者预后不良相关,无论治疗方法如何。
我们回顾性研究了高万古霉素最低抑菌浓度(MIC > 2 μg/ml)对53例甲氧西林敏感金黄色葡萄球菌(MSSA)所致菌血症的影响。采用微量肉汤稀释法测定万古霉素MIC。主要终点为自首次血培养阳性之日起30天的全因死亡率。死亡率为22.6%(53例中有12例)。万古霉素MIC高(优势比(OR) = 9.3;95%置信区间(95% CI) = 1.31-63.20;p = 0.027), Charlson合并症指数≥3 (OR = 10.3;95% ci = 1.3-102.04;p = 0.03)、高龄(OR = 35.8;95% ci = 2.3-659.2;p = 0.01),严重脓毒症(OR = 8.5;95% ci = 1.2-61.4;P = 0.03)与死亡率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊最新文献
Risk of neonatal and childhood morbidity among preterm infants exposed to marijuana. Performance of the Simplexa™ Flu A/B & RSV Direct Kit on respiratory samples collected in saline solution. Elevated levels of circulating histones indicate disease activity in patients with hand, foot, and mouth disease (HFMD). The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1